Originally published by Crystal Pharmatech. Republished with company attribution. Original technical perspectives, references and source links are retained.
When a compound is both solubility- and permeability-limited, the reflex is often to reach for an Amorphous Solid Dispersion. But is that always the right move?
For this compound, we need to take a systematic approach. The key question is whether absorption is primarily limited by solubility or by permeability — and the answer is rarely obvious from the label alone.
Breaking Down the Decision Framework
When faced with a "double-limited" compound, there are three distinct scenarios that lead to fundamentally different formulation paths. Understanding which scenario you're actually in is the entire game.
- Scenario 1 — Permeability is the true bottleneck: If solubility enhancement does not lead to improved bioavailability, the compound is likely permeability-limited. In this case, an ASD, which primarily enhances apparent solubility and dissolution rate, may not provide meaningful benefit, regardless of how well it's formulated.
- Scenario 2 — Solubility is the true bottleneck:If solubility enhancement results in improved bioavailability, the compound is likely solubility-limited. In that scenario, ASD represents a rational and worthwhile strategy. Other enabling approaches may also be considered, such as salt formation or lipid-based formulations.
- Scenario 3 — The picture is still unclear: If it is not yet clear whether the compound is solubility-limited or permeability-limited, ASD may still be explored as part of a broader formulation screening strategy, alongside other enabling technologies — but as a candidate, not a conclusion.
"However, its selection should be guided by experimental evidence rather than assumption."